

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10790662	
	Filing Date		2004-03-01	
	First Named Inventor	David J. Chaplin		
	Art Unit	1617		
	Examiner Name	San Ming R. HUI		
	Attorney Docket Number	OXGN-019.US1		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030129223		2003-07-10	Wartchow et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	98/39323	WO			Baylor University		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10790662
Filing Date	2004-03-01
First Named Inventor	David J. Chaplin
Art Unit	1617
Examiner Name	San Ming R. HUI
Attorney Docket Number	OXGN-019.US1

1	GRIGGS et al., "Potent anti-metastatic activity of combretastatin." International Journal of Oncology, 19, (2001), pp. 821-825.	<input type="checkbox"/>
2	GRIGGS et al., "Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4." American Journal of Pathology, Vol. 160, No. 3, (March 2002), pp. 1097-1103.	<input type="checkbox"/>
3	RONJIANI et al., "Activity of the vascular Targeting Agent Combretastatin A-4 Disodium Phosphate in a Xenograft Model of AIDS-Associated Kaposi's Sarcoma." Taylor & Francis, (2002), pp. 98-105.	<input type="checkbox"/>
4	Barcher et al., "D-24851, a Novel Synthetic Microtubule Inhibitor, Exerts Curative Antitumoral Activity in Vivo, Shows Efficacy toward Multidrug-resistant Tumor Cells, and Lacks Neurotoxicity." Cancer, Vol. 61, (January 1, 2001), pp. 392-399.	<input type="checkbox"/>
5	Combeau et al., "RPR112378 and RPR115781: Two Representatives of a New Family of Microtubule Assembly Inhibitors." Molecular Pharmacology, Vol. 57, (2000), pp. 553-563.	<input type="checkbox"/>
6	Hammond et al., "Studies to show that with podophyllotoxin the early replicative stages of herpes simplex virus type 1 depend upon functional cytoplasmic microtubules." J. Med. Microbiol., Vol. 45, (1996), pp. 167-172.	<input type="checkbox"/>
7	Kanoh et al., "(-)-Phenylahistin Arrest Cells in Mitosis by Inhibiting Tubulin Polymerization." The Journal of Antibiotics, Vol. 52, No.2, (Feb. 1999), pp. 134-141.	<input type="checkbox"/>
8	Leoni et al., "Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells." J. Natl. Cancer Inst., Vol. 92, (2000), pp. 217-224.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/San Ming Hui/	Date Considered	02/12/2012
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.